Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 515-524 , July 2009

[186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model

  • Anuradha Soundararajan

      Affiliations

    • Department of Radiology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • ,
  • Ande Bao

      Affiliations

    • Department of Radiology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • Department of Otolaryngology—Head and Neck Surgery, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • ,
  • William T. Phillips

      Affiliations

    • Department of Radiology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • ,
  • Ricardo Perez III

      Affiliations

    • Department of Radiology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • ,
  • Beth A. Goins

      Affiliations

    • Department of Radiology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 210 567 5575; fax: +1 210 567 5549.

Received 19 December 2008 ,Revised 14 February 2009 ,Accepted 18 February 2009.

References 

  1. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424–436
  2. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419–436
  3. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res. 1993;10:703–708
  4. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006;16:175–183
  5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  6. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–194
  7. Kies MS, Bennett CL, Vokes EE. Locally advanced head and neck cancer. Curr Treat Options Oncol. 2001;2:7–13
  8. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007;25:4118–4126
  9. Vokes EE. Interactions of chemotherapy and radiation. Semin Oncol. 1993;20:70–79
  10. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer. 2001;37:2015–2022
  11. Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol. 2000;46:10–18
  12. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res. 2000;6:4939–4949
  13. Mitra A, Nan A, Line BR, Ghandehari H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des. 2006;12:4729–4749
  14. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med. 2003;44:1992–1999
  15. Wang SX, Bao A, Herrera SJ, Phillips WT, Goins B, Santoyo C, et al. Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res. 2008;14:3975–3983
  16. Zavaleta CL, Goins BA, Bao A, McManus LM, McMahan CA, Phillips WT. Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Target. 2008;16:626–637
  17. Chang YJ, Chang CH, Chang TJ, Yu CY, Chen LC, Jan ML, et al. Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 2007;27:2217–2225
  18. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, et al. Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol. 2007;34:415–423
  19. Chen LC, Chang CH, Yu CY, Chang YJ, Wu YH, Lee WC, et al. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol. 2008;35:883–893
  20. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide–liposome conjugates in internal radiotherapy. J Nucl Med. 2001;42:499–504
  21. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome–radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res. 2000;20:3339–3345
  22. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol. 1996;41:1905–1914
  23. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther. 2004;308:419–425
  24. Bao A, Phillips WT, Goins B, McGuff HS, Zheng X, Woolley FR, et al. Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. Otolaryngol Head Neck Surg. 2006;135:853–857
  25. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148–154
  26. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol. 2005;16:1365–1371
  27. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst. 1989;81:1484–1488
  28. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104:10–14
  29. Chonn A, Semple SC, Cullis PR. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta. 1991;1070:215–222
  30. Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev. 1999;37:13–32
  31. Hafeli U, Tiefenauer LX, Schbiger PA, Weder HG. A lipophilic complex with 186Re/188Re incorporated in liposomes suitable for radiotherapy. Int J Rad Appl Instrum B. 1991;18:449–454
  32. McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci. 2005;7:29–34
  33. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298:607–612
  34. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149–168
  35. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85:6949–6953
  36. Lee CM, Choi Y, Huh EJ, Lee KY, Song HC, Sun MJ, et al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother Radiopharm. 2005;20:620–628
  37. Awasthi VD, Garcia D, Goins BA, Phillips WT. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm. 2003;253:121–132
  38. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591–607
  39. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–212
  40. Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med. 2008;49:1506–1511
  41. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol. 2004;31:196–205
  42. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740
  43. Laginha KM, Moase EH, Yu N, Huang A, Allen TM. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target. 2008;16:605–610
  44. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys. 2006;66:S89–S95

PII: S0969-8051(09)00050-X

doi: 10.1016/j.nucmedbio.2009.02.004

Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 515-524 , July 2009

Article Tools

* Image Usage & Resolution